Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 35
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum

  • Gajate, Consuelo
  • Matos-da-Silva, Marcia
  • Dakir, El Habib
  • Fonteriz, Rosalba I.
  • Álvarez, Javier
  • Mollinedo, Faustino
Pancreatic cancer remains as one of the most deadly cancers, and responds poorly to current therapies. The prognosis is extremely poor, with a 5-year survival of less than 5%. Therefore, search for new effective therapeutic drugs is of pivotal need and urgency to improve treatment of this incurable malignancy. Synthetic alkyl-lysophospholipid analogs (ALPs) constitute a heterogeneous group of unnatural lipids that promote apoptosis in a wide variety of tumor cells. In this study, we found that the anticancer drug edelfosine was the most potent ALP in killing human pancreatic cancer cells, targeting endoplasmic reticulum (ER). Edelfosine was taken up in significant amounts by pancreatic cancer cells and induced caspase- and mitochondrial-mediated apoptosis. Pancreatic cancer cells show a prominent ER and edelfosine accumulated in this subcellular structure, inducing a potent ER stress response, with caspase-4, BAP31 and c-Jun NH2-terminal kinase (JNK) activation, CHOP/GADD153 upregulation and phosphorylation of eukaryotic translation initiation factor 2 α-subunit that eventually led to cell death. Oral administration of edelfosine in xenograft mouse models of pancreatic cancer induced a significant regression in tumor growth and an increase in apoptotic index, as assessed by TUNEL assay and caspase-3 activation in the tumor sections. The ER stress-associated marker CHOP/GADD153 was visualized in the pancreatic tumor isolated from edelfosine-treated mice, indicating a strong in vivo ER stress response. These results suggest that edelfosine exerts its pro-apoptotic action in pancreatic cancer cells, both in vitro and in vivo, through its accumulation in the ER, which leads to ER stress and apoptosis. Thus, we propose that the ER could be a key target in pancreatic cancer, and edelfosine may constitute a prototype for the development of a new class of antitumor drugs targeting the ER., This work was supported by grants from Fondo de Investigación Sanitaria and European Commission (FIS-FEDER PS09/ 01915), Ministerio de Ciencia e Innovación (SAF2008-02251, BFU 2008-01871 and RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III), European Community’s Seventh Framework Programme FP7-2007-2013 (Grant HEALTH-F2-2011-256986) and Junta de Castilla y León (CSI052A11-2, GR15-Experimental Therapeutics and Translational Oncology Program, Biomedicine Project 2009 and Biomedicine Project 2010-2011). CG is supported by the Ramón y Cajal Program from the Ministerio de Ciencia e Innovación of Spain., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lipid rafts and fas/CD95 signaling in cancer chemotherapy

  • Mollinedo, Faustino
  • Gajate, Consuelo
Cholesterol- and sphingolipid-rich membrane domains, termed lipid rafts, have been recently involved in the triggering of death receptor-mediated apoptosis. The alkyl-lysophospholipid analogue edelfosine was the first antitumor drug reported to induce apoptosis in cancer cells through co-clustering of lipid rafts and Fas/CD95 death receptor. Recruitment and aggregation of Fas/CD95 in lipid raft clusters was independent of its cognate ligand FasL/CD95L, and could be pharmacologically modulated. The adaptor molecule Fas-associated death domain protein (FADD) and procaspase- 8 were also recruited into lipid rafts following edelfosine treatment, forming the death-inducing signaling complex (DISC), and hence these membrane microdomains can act as scaffolds for Fas/CD95 death signaling. Edelfosine accumulated in lipid rafts of cancer cells, altering raft protein and lipid composition. Subsequently, an increasing number of antitumor drugs have been found to induce apoptosis through recruitment of Fas/CD95 into membrane rafts, and some of these compounds accumulated in raft membrane domains. Additional downstream apoptotic signaling molecules have also been reported to be recruited into rafts following treatment of cancer cells with antitumor agents, thus facilitating proteinprotein interactions and conveying apoptotic signals. On these grounds, lipid rafts have become an appealing and promising target for therapeutic intervention in cancer chemotherapy. Co-clustering of lipid rafts and Fas/CD95 signaling provides a new insight in the regulation of death receptor-mediated apoptosis, opening a new avenue in cancer therapy. In this regard, an increasing number of patents are dealing with the above insights in order to improve cancer treatment., Ministerio de Ciencia e Innovación of Spain (SAF2008-02251, and RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), Fondo de Investigación Sanitaria and European Commission (PS09/01915), European Community’s Seventh Framework Programme (FP7-HEALTH-2010/256986), and Junta de Castilla y León (GR15-Experimental Therapeutics and Translational Oncology Program, and Biomedicine Projects 2009 and 2010-2011). C.G. is supported by the Ramón y Cajal Program from the Spanish Ministerio de Ciencia e Innovación., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The plasma membrane: A catalyst in the decision to die or not to die?

  • Legembre, Patrick
  • Mollinedo, Faustino
Editorial [Hot topic: Stresses, Death Receptors and Plasma Membrane (Guest Editors: Patrick Legembre and Faustino Mollinedo)]., Induction of cell death plays a crucial role in morphogenesis, homeostasis, immune tolerance and surveillance and chemotherapy. Supernumerary, damaged, transformed, or infected cells can be eliminated through intrinsic or extrinsic cell death programs. The induction of the extrinsic signal occurs when cytokines (i.e., CD95L, TRAIL, TNF-α) present in serum or anchored in immune cells (e.g., T-lymphocytes, natural killer cells) bind to their respective death receptors, namely CD95 (also called APO-1 or Fas), DR4 and DR5 or TNF-R1. Interaction with the ligand orchestrates aggregation and conformational alteration of the death receptors, whose intracellular domains recruit adaptor proteins (i.e., TRADD, FADD), which in turn drive, through protein/protein interactions, the induction of caspases evoking the death program., Ministerio de Ciencia e Innovación of Spain (SAF2008-02251, and RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986), and Junta de Castilla y León (CSI052A11-2, GR15-Experimental Therapeutics and Translational Oncology Program, and Biomedicine Project 2009)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria

  • Mollinedo, Faustino
  • Hornillos, Valentín
  • Delgado, Javier
  • Amat-Guerri, Francisco
  • Acuña, A. Ulises
  • Nieto-Miguel, Teresa
  • Villa-Pulgarín, J. A.
  • Gajate, Consuelo
This work is licensed under the Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported License.-- et al., Lipid rafts and mitochondria are promising targets in cancer therapy. The synthetic antitumor alkyl-lysophospholipid analog edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) has been reported to target lipid rafts. Here, we have found that edelfosine induced loss of mitochondrial membrane potential and apoptosis in human cervical carcinoma HeLa cells, both responses being abrogated by Bcl-xL overexpression. We synthesized a number of new fluorescent edelfosine analogs, which preserved the proapoptotic activity of the parent drug, and colocalized with mitochondria in HeLa cells. Edelfosine induced swelling in isolated mitochondria, indicating an increase in mitochondrial membrane permeability. This mitochondrial swelling was independent of reactive oxygen species generation. A structurally related inactive analog was unable to promote mitochondrial swelling, highlighting the importance of edelfosine molecular structure in its effect on mitochondria. Raft disruption inhibited mitochondrial localization of the drug in cells and edelfosine-induced swelling in isolated mitochondria. Edelfosine promoted a redistribution of lipid rafts from the plasma membrane to mitochondria, suggesting a raft-mediated link between plasma membrane and mitochondria. Our data suggest that direct interaction of edelfosine with mitochondria eventually leads to mitochondrial dysfunction and apoptosis. These observations unveil a new framework in cancer chemotherapy that involves a link between lipid rafts and mitochondria in the mechanism of action of an antitumor drug, thus opening new avenues for cancer treatment., This work was supported by the Spanish Ministerio de Ciencia e Innovación (SAF2008-02251, BQU2003-4413 and RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), Fondo de Investigación Sanitaria and European Commission (FIS-FEDER 06/0813, 08/1434, PS09/01915), European Community's Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986), Junta de Castilla y León (CSI052A11-2, GR15-Experimental Therapeutics and Translational Oncology Program, Biomedicine Project 2009 and Biomedicine Project 2010-2011), Fundación para la Investigación Sanitaria en Castilla-La Mancha (FISCAM, PI-2006/10) and Junta de Comunidades de Castilla-La Mancha (I1I09-0163-4002). CG is supported by the Ramón y Cajal Program from the Spanish Ministerio de Ciencia e Innovación. MF is recipient of a postdoctoral fellowship from Fondo de Investigación Sanitaria. VH is recipient of a predoctoral fellowship from the Spanish Ministerio de Ciencia e Innovación., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites

  • Varela-M, Rubén E.
  • Villa-Pulgarín, J. A.
  • Yepes, Edward
  • Pandiella, Atanasio
  • Muro, Antonio
  • Mollinedo, Faustino
This is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al., [Background]: The leishmaniases are a complex of neglected tropical diseases caused by more than 20 Leishmania parasite species, for which available therapeutic arsenal is scarce and unsatisfactory. Pentavalent antimonials (SbV) are currently the first-line pharmacologic therapy for leishmaniasis worldwide, but resistance to these compounds is increasingly reported. Alkyl-lysophospoholipid analogs (ALPs) constitute a family of compounds with antileishmanial activity, and one of its members, miltefosine, has been approved as the first oral treatment for visceral and cutaneous leishmaniasis. However, its clinical use can be challenged by less impressive efficiency in patients infected with some Leishmania species, including L. braziliensis and L. mexicana, and by proneness to develop drug resistance in vitro. [Methodology/Principal Findings]: We found that ALPs ranked edelfosine.perifosine.miltefosine.erucylphosphocholine for their antileishmanial activity and capacity to promote apoptosis-like parasitic cell death in promastigote and amastigote forms of distinct Leishmania spp., as assessed by proliferation and flow cytometry assays. Effective antileishmanial ALP concentrations were dependent on both the parasite species and their development stage. Edelfosine accumulated in and killed intracellular Leishmania parasites within macrophages. In vivo antileishmanial activity was demonstrated following oral treatment with edelfosine of mice and hamsters infected with L. major, L. panamensis or L. braziliensis, without any significant side-effect. Edelfosine also killed SbV-resistant Leishmania parasites in in vitro and in vivo assays, and required longer incubation times than miltefosine to generate drug resistance. [Conclusions/Significance]: Our data reveal that edelfosine is the most potent ALP in killing different Leishmania spp., and it is less prone to lead to drug resistance development than miltefosine. Edelfosine is effective in killing Leishmania in culture and within macrophages, as well as in animal models infected with different Leishmania spp. and SbV-resistant parasites. Our results indicate that edelfosine is a promising orally administered antileishmanial drug for clinical evaluation., This work was supported by the Spanish Ministerio de Ciencia e Innovación (SAF2008-02251; SAF2011-30518; RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union; and TRA2009-0275), European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986), Junta de Castilla y León (CSI052A11-2; GR15-Experimental Therapeutics and Translational Oncology Program) and Spain-UK International Joint Project grant from The Royal Society-CSIC (2004GB0032)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients

  • Santamaría, Carlos
  • Muntión, Sandra
  • Rosón, Beatriz
  • Blanco, Belén
  • López-Villar, Olga
  • Carrancio, Soraya
  • Sánchez-Guijo, Fermín M.
  • Díez-Campelo, María
  • Álvarez-Fernández, Stela
  • Sarasquete, María Eugenia
  • De Las Rivas, Javier
  • González, Marcos
  • San Miguel, Jesús F.
  • Cañizo, María Consuelo del
This is an open-access paper., [Background]: Recent findings suggest that a specific deletion of Dicer1 in mesenchymal stromal cells-derived osteoprogenitors triggers several features of myelodysplastic syndrome in a murine model. Our aim was to analyze DICER1 and DROSHA gene and protein expression in mesenchymal stromal cells (the osteoblastic progenitors) obtained from bone marrow of myelodysplastic syndrome patients, in addition to microRNA expression profile and other target genes such as SBDS, a DICER1-related gene that promotes bone marrow dysfunction and myelodysplasia when repressed in a murine model. [Design and Methods]: Mesenchymal stromal cells from 33 bone marrow samples were evaluated. DICER, DROSHA and SBDS gene expression levels were assessed by real-time PCR and protein expression by Western blot. MicroRNA expresion profile was analyzed by commercial low-density arrays and some of these results were confirmed by individual real-time PCR. [Results]: Mesenchymal stromal cells from myelodysplastic syndrome patients showed lower DICER1 (0.65±0.08 vs. 1.91±0.57; P=0.011) and DROSHA (0.62±0.06 vs. 1.38±0.29; P=0.009) gene expression levels, two relevant endonucleases associated to microRNA biogenesis, in comparison to normal myelodysplastic syndrome. These findings were confirmed at protein levels by Western blot. Strikingly, no differences were observed between paired mononuclear cells from myelodysplastic syndrome and controls. In addition, mesenchymal stromal cells from myelodysplastic syndrome patients showed significant lower SBDS (0.63±0.06 vs. 1.15±0.28; P=0.021) gene expression levels than mesenchymal stromal cells from healthy controls. Furthermore, mesenchymal stromal cells from myelodysplastic syndrome patients showed an underlying microRNA repression compared to healthy controls. Real-time PCR approach confirmed that mir-155, miR-181a and miR- 222 were down-expressed in mesenchymal stromal cells from myelodysplastic syndrome patients. [Conclusions]: This is the first description of an impaired microRNA biogenesis in human mesenchymal stromal cells from myelodysplastic syndrome patients, where DICER1 and DROSHA gene and protein downregulation correlated to a gene and microRNA abnormal expression profile, validating the animal model results previously described., Grants from Consejeria de Educacion de la Junta de Castilla y León (HUS03A09) and Instituto de Salud Carlos III (FIS09/01530)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma

  • Estella-Hermoso de Mendoza, A.
  • Préat, Veronique
  • Mollinedo, Faustino
  • Blanco-Prieto, María J.
Edelfosine is the prototype molecule of a family of anticancer drugs collectively known as synthetic alkyl-lysophospholipids. This drug holds promise as a selective antitumor agent, and a number of preclinical assays are in progress. In this study, we observe the accumulation of edelfosine in brain tissue after its oral administration in Compritol (R) and Precirol (R) lipid nanoparticles (LN). The high accumulation of edelfosine in brain was due to the inhibition of P-glycoprotein by Tween (R) 80, as verified using a P-glycoprotein drug interaction assay. Moreover, these LN were tested in vitro against the C6 glioma cell line, which was later employed to establish an in vivo xenograft mouse model of glioma. In vitro studies revealed that edelfosine-loaded LN induced an antiproliferative effect in C6 glioma cell line. In addition, in vivo oral administration of drug-loaded LN in NMRI nude mice bearing a C6 glioma xenograft tumor induced a highly significant reduction in tumor growth (p<0.01) 14 days after the beginning of the treatment. Our results showed that Tween (R) 80 coated Compritol (R) and Precirol (R) LN can effectively inhibit the growth of C6 glioma cells in vitro and suggest that edelfosine-loaded LN represent an attractive option for the enhancement of antitumor activity on brain tumors in vivo., Caja Navarra Foundation, Ibercaja, the Government of Navarra, Department of Health (“Ortiz de Landázuri” fellowship, ref: 63/09), the Spanish Ministry of Science and Innovation (SAF2007-61261, SAF2008-02251, SAF2010-15547, PCT-090100-2007-27, RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union) and University of Navarra (FUN). Ander Estella-Hermoso de Mendoza is supported by a research grant from the Department of Education of the Basque Government (BFI06.37)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Depletion of L-arginine induces autophagy as a cytoprotective response to endoplasmic reticulum stress in human T lymphocytes

  • García-Navas, Rósula
  • Munder, Markus
  • Mollinedo, Faustino
PMCID: PMC3494587, L-arginine (L-Arg) deficiency results in decreased T-cell proliferation and impaired T-cell function. Here we have found that L-Arg depletion inhibited expression of different membrane antigens, including CD247 (CD3ζ), and led to an ER stress response, as well as cell cycle arrest at G(0)/G(1) in both human Jurkat and peripheral blood mitogen-activated T cells, without undergoing apoptosis. By genetic and biochemical approaches, we found that L-Arg depletion also induced autophagy. Deprivation of L-Arg induced EIF2S1 (eIF2α), MAPK8 (JNK), BCL2 (Bcl-2) phosphorylation, and displacement of BECN1 (Beclin 1) binding to BCL2, leading to autophagosome formation. Silencing of ERN1 (IRE1α) prevented the induction of autophagy as well as MAPK8 activation, BCL2 phosphorylation and XBP1 splicing, whereas led T lymphocytes to apoptosis under L-Arg starvation, suggesting that the ERN1-MAPK8 pathway plays a major role in the activation of autophagy following L-Arg depletion. Autophagy was required for survival of T lymphocytes in the absence of L-Arg, and resulted in a reversible process. Replenishment of L-Arg made T lymphocytes to regain the normal cell cycle profile and proliferate, whereas autophagy was inhibited. Inhibition of autophagy by ERN1, BECN1 and ATG7 silencing, or by pharmacological inhibitors, promoted cell death of T lymphocytes incubated in the absence of L-Arg. Our data indicate for the first time that depletion of L-Arg in T lymphocytes leads to a reversible response that preserves T lymphocytes through ER stress and autophagy, while remaining arrested at G(0)/G(1). Our data also show that the L-Arg depletion-induced ER stress response could lead to apoptosis when autophagy is blocked., This work was supported by the Spanish Ministerio de Ciencia e Innovación (SAF2008-02251, SAF2011-30518, and RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986), Junta de Castilla y León (CSI052A11-2, GR15-Experimental Therapeutics and Translational Oncology Program, Biomedicine Project 2009), and Acciones Integradas Spain-Germany (HA2007-0080)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma

  • Reis-Sobreiro, M.
  • Roué, Gaël
  • Moros, A.
  • Gajate, Consuelo
  • Iglesia-Vicente, Janis de la
  • Colomer, Dolors
  • Mollinedo, Faustino
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License., Recent evidence shows that lipid raft membrane domains modulate both cell survival and death. Here, we have found that the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway is present in the lipid rafts of mantle cell lymphoma (MCL) cells, and this location seems to be critical for full activation and MCL cell survival. The antitumor lipids (ATLs) edelfosine and perifosine target rafts, and we found that ATLs exerted in vitro and in vivo antitumor activity against MCL cells by displacing Akt as well as key regulatory kinases p-PDK1 (phosphatidylinositol-dependent protein kinase 1), PI3K and mTOR (mammalian TOR) from lipid rafts. This raft reorganization led to Akt dephosphorylation, while proapoptotic Fas/CD95 death receptor was recruited into rafts. Raft integrity was critical for Ser473 Akt phosphorylation. ATL-induced apoptosis appeared to correlate with the basal Akt phosphorylation status in MCL cell lines and primary cultures, and could be potentiated by the PI3K inhibitor wortmannin, or inhibited by the Akt activator pervanadate. Classical Akt inhibitors induced apoptosis in MCL cells. Microenvironmental stimuli, such as CD40 ligation or stromal cell contact, did not prevent ATL-induced apoptosis in MCL cell lines and patient-derived cells. These results highlight the role of raft-mediated PI3K/Akt signaling in MCL cell survival and chemotherapy, thus becoming a new target for MCL treatment. © 2013 Macmillan Publishers Limited., This work was supported by grants from Ministerio de Economía y Competitividad of Spain (SAF2008-02251 and SAF2011-30518 to FM; SAF2009-09503 to DC), Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union (RD06/0020/1037 and RD12/0036/0065 to FM; RD06/0020/0014 to DC), Fondo de Investigación Sanitaria and European Commission, Instituto de Salud Carlos III (PI09/0060 to GR; PS09/01915 to CG), European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS to FM), Junta de Castilla y León (CSI052A11-2 and CSI221A12-2 to FM; Biomedicine Project 2010–2011 to CG) and Generalitat de Catalunya (2009SGR967 to DC). MRS was recipient of a predoctoral fellowship from the Fundaçâo para a Ciência e Tecnologia (Ministério da Ciencia, Tecnología e Ensino Superior of Portugal), and AM was a recipient of a predoctoral fellowship from IDIBAPS. CG was supported by the Ramón y Cajal Program from the Ministerio de Ciencia e Innovación of Spain., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Lipid rafts, cholesterol and apoptosis in cancer and neurodegenerative diseases

  • Mollinedo, Faustino
  • Gajate, Consuelo
The dynamic nature of membrane along with an uneven distribution of lipids leads to the formation of specialized membrane domains where proteins can selectively be included or excluded. In this regard, the dynamic and preferential clustering and packing of sphingolipids and cholesterol into moving platforms, named as lipid rafts, form membrane domains that act as scaffolds for the attachment of specific proteins and for the proper functioning of a number of signaling cascades. Lipid rafts harbor several signaling routes that promote cell survival and proliferation, and thereby they could play a role in the development of cancer. On the other hand, evidences in the last decade have shown that lipid rafts can also serve as organizing centers for the assembly of apoptotic and signaling molecules involved in cell death, thus opening a new avenue in cancer therapy. Recruitment of death receptors and downstream apoptotic signaling molecules in aggregated lipid rafts has led to the emerging concept of a plasma membrane platform designated as “cluster of apoptotic signaling molecule-enriched rafts” (CASMER) that may play a role in the regulation of apoptosis. In addition, lipid rafts also play a major role in neurotoxicity, including the production and aggregation of amyloid-β peptide (Aβ) to form neurotoxic Aβ oligomers in the brain, which are widely believed to drive Alzheimer’s disease pathology. Alterations in cholesterol have been detected in cell models for cancer and neurodegenerative diseases, which might lead to changes in cholesterol-rich rafts and thereby in the regulation of cell death or survival. However, it is currently unclear what the potential mechanisms underlying cholesterol perturbations are. Growing evidence suggests that compartmentalization of macrocomplexes and signaling routes in lipid rafts has a crucial role in the regulation of cell fate, being of major importance in different pathologies, including cancer and neurodegenerative diseases. Despite the underlying mechanisms and functional impact of protein compartmentalization are still not well understood, the modulation of lipid rafts opens new approaches in the treatment of these diseases for which current available therapies are not satisfactory., This work was supported by grants from the Spanish Ministerio de Ciencia e Innovación (SAF2008-02251, SAF2011-30518, and RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986), Junta de Castilla y León (CSI052A11-2, GR15-Experimental Therapeutics and Translational Oncology Program, Biomedicine Project 2009, and Biomedicine Project 2010-2011) to F.M.; grants from the Fondo de Investigación Sanitaria and European Commission (FIS-FEDER 06/0813, PS09/01915) to C.G. C.G. is supported by the Ramón y Cajal Program from the Spanish Ministerio de Ciencia e Innovación., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast

  • Cuesta-Marbán, Álvaro
  • Botet, Javier
  • Czyz, Ola
  • Cacharro, Luis M.
  • Gajate, Consuelo
  • Hornillos, Valentín
  • Delgado, Javier
  • Zhang, Hui
  • Amat-Guerri, Francisco
  • Acuña, A. Ulises
  • McMaster, Christopher R.
  • Revuelta Doval, José Luis
  • Zaremberg, Vanina
  • Mollinedo, Faustino
The ether-phospholipid edelfosine, a prototype antitumor lipid (ATL), kills yeast cells and selectively kills several cancer cell types. To gain insight into its mechanism of action, we performed chemogenomic screens in the Saccharomyces cerevisiae gene-deletion strain collection, identifying edelfosine-resistant mutants. LEM3, AGP2, and DOC1 genes were required for drug uptake. Edelfosine displaced the essential proton pump Pma1p from rafts, inducing its internalization into the vacuole. Additional ATLs, including miltefosine and perifosine, also displaced Pma1p from rafts to the vacuole, suggesting that this process is a major hallmark of ATL cytotoxicity in yeast. Radioactive and synthetic fluorescent edelfosine analogues accumulated in yeast plasma membrane rafts and subsequently the endoplasmic reticulum. Although both edelfosine and Pma1p were initially located at membrane rafts, internalization of the drug toward endoplasmic reticulum and Pma1p to the vacuole followed different routes. Drug internalization was not dependent on endocytosis and was not critical for yeast cytotoxicity. However, mutants affecting endocytosis, vesicle sorting, or trafficking to the vacuole, including the retromer and ESCRT complexes, prevented Pma1p internalization and were edelfosineresistant. Our data suggest that edelfosine-induced cytotoxicity involves raft reorganization and retromer- and ESCRT-mediated vesicular transport and degradation of essential raft proteins leading to cell death. Cytotoxicity of ATLs is mainly dependent on the changes they induce in plasma membrane raft-located proteins that lead to their internalization and subsequent degradation. Edelfosine toxicity can be circumvented by inactivating genes that then result in the recycling of internalized cell-surface proteins back to the plasma membrane. © 2013 by The American Society for Biochemistry and Molecular Biology, Inc., This work was supported in part by Spanish Ministerio de Economia y Competitividad Grants SAF2005-04293, SAF2008-02251, and SAF2011-30518, Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, co-funded by the Fondo Europeo de Desarrollo Regional of the European Union Grants RD06/0020/1037 and RD12/0036/0065, European Community's Seventh Framework Programme FP7-2007-2013 Grant HEALTH-F2-2011-256986 (PANACREAS), Fundación “la Caixa” Grant BM05-30-0, Junta de Castilla y León Grants CSI052A11-2 and CSI221A12-2 (to F. M.), Spanish Ministerio de Economia y Competitividad Grants BIO2008-00194 and BIO2011-23901, Junta de Castilla y León Grant GR147 (to J. L. R.), Fondo de Investigación Sanitaria and European Commission (FIS-FEDER) Grants 06/0813 and PS09/01915, Junta de Castilla y León Biomedicine Project 2010-2011 (to C. G.), Spanish Ministerio de Economia y Competitividad Grant CTQ2010-16457 (to A. U. A.), Canadian Institutes of Health Research Grant 14124 (to C. R. M.), a Natural Sciences and Engineering Research Council of Canada discovery grant, a seed grant from the University of Calgary, and an Natural Sciences and Engineering Research Council of Canada University faculty award (to V. Z.)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Alteration of plasma membrane organization by an anticancer lysophosphatidylcholine analogue induces intracellular acidification and internalization of plasma membrane transporters in yeast

  • Czyz, Ola
  • Bitew, Teshager
  • Cuesta-Marbán, Álvaro
  • McMaster, Christopher R.
  • Mollinedo, Faustino
  • Zaremberg, Vanina
The lysophosphatidylcholine analogue edelfosine is a potent antitumor lipid that targets cellular membranes. The underlying mechanisms leading to cell death remain controversial, although two cellular membranes have emerged as primary targets of edelfosine, the plasma membrane (PM) and the endoplasmic reticulum. In an effort to identify conditions that enhance or prevent the cytotoxic effect of edelfosine, we have conducted genome-wide surveys of edelfosine sensitivity and resistance in Saccharomyces cerevisiae presented in this work and the accompanying paper (Cuesta-Marbán, Á., Botet, J., Czyz, O., Cacharro, L. M., Gajate, C., Hornillos, V., Delgado, J., Zhang, H., Amat-Guerri, F., Acuña, A. U., McMaster, C. R., Revuelta, J. L., Zaremberg, V., and Mollinedo, F. (January 23, 2013) J. Biol. Chem. 288,), respectively. Our results point to maintenance of pH homeostasis as a major player in modulating susceptibility to edelfosine with the PM proton pump Pma1p playing a main role. We demonstrate that edelfosine alters PM organization and induces intracellular acidification. Significantly, we show that edelfosine selectively reduces lateral segregation of PM proteins like Pma1p and nutrient H+-symporters inducing their ubiquitination and internalization. The biology associated to the mode of action of edelfosine we have unveiled includes selective modification of lipid raft integrity altering pH homeostasis, which in turn regulates cell growth. © 2013 by The American Society for Biochemistry and Molecular Biology, Inc., This work was supported in part by a Natural Sciences and Engineering Research Council of Canada discovery grant, a seed grant from the University of Calgary, a Natural Sciences and Engineering Research Council of Canada University Faculty award (to V. Z.), Canadian Institutes of Health Research Grant 14124 (to C. R. M.), Spanish Ministerio de Economia y Competitividad Grants SAF2008-02251 and SAF2011-30518, Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, co-funded by the Fondo Europeo de Desarrollo Regional of the European Union Grants RD06/0020/1037 and RD12/0036/0065, European Community's Seventh Framework Programme FP7-2007-2013 Grant HEALTH-F2-2011-256986, (PANACREAS), and Junta de Castilla y León Grants CSI052A11-2 and CSI221A12-2 (to F. M.)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lipid raft involvement in yeast cell growth and death

  • Mollinedo, Faustino
This is an open-access article distributed under the terms of the Creative Commons Attribution License., The notion that cellular membranes contain distinct microdomains, acting as scaffolds for signal transduction processes, has gained considerable momentum. In particular, a class of such domains that is rich in sphingolipids and cholesterol, termed as lipid rafts, is thought to compartmentalize the plasma membrane, and to have important roles in survival and cell death signaling in mammalian cells. Likewise, yeast lipid rafts are membrane domains enriched in sphingolipids and ergosterol, the yeast counterpart of mammalian cholesterol. Sterol-rich membrane domains have been identified in several fungal species, including the budding yeast Saccharomyces cerevisiae, the fission yeast Schizosaccharomyces pombe as well as the pathogens Candida albicans and Cryptococcus neoformans. Yeast rafts have been mainly involved in membrane trafficking, but increasing evidence implicates rafts in a wide range of additional cellular processes. Yeast lipid rafts house biologically important proteins involved in the proper function of yeast, such as proteins that control Na+, K+, and pH homeostasis, which influence many cellular processes, including cell growth and death. Membrane raft constituents affect drug susceptibility, and drugs interacting with sterols alter raft composition and membrane integrity, leading to yeast cell death. Because of the genetic tractability of yeast, analysis of yeast rafts could be an excellent model to approach unanswered questions of mammalian raft biology, and to understand the role of lipid rafts in the regulation of cell death and survival in human cells. A better insight in raft biology might lead to envisage new raft-mediated approaches to the treatment of human diseases where regulation of cell death and survival is critical, such as cancer and neurodegenerative diseases., Our laboratory is supported by the following funding agencies: Spanish Ministerio de Economia y Competitividad (SAF2011-30518,and RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, co-funded by the Fondo Europeo de Desarrollo Regional of the EuropeanUnion), European Community’s Seventh Framework Programme FP7-2007-2013 (grantHEALTH-F2-2011-256986, PANACREAS), and Junta de Castilla y León (CSI052A11-2, and CSI221A12-2)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Endowing indole-based tubulin inhibitors with an anchor for derivatization: highly potent 3-substituted indolephenstatins and indoleisocombretastatins

  • Álvarez, Raquel
  • Díaz, José Fernando
  • Bento, Ana C.
  • García-Navas, Rósula
  • Iglesia-Vicente, Janis de la
  • Mollinedo, Faustino
  • Andreu, José Manuel
  • Peláez, Rafael
Colchicine site ligands with indole B rings are potent tubulin polymerization inhibitors. Structural modifications at the indole 3-position of 1-methyl-5-indolyl-based isocombretastatins (1,1-diarylethenes) and phenstatins endowed them with anchors for further derivatization and resulted in highly potent compounds. The substituted derivatives displayed potent cytotoxicity against several human cancer cell lines due to tubulin inhibition, as shown by cell cycle analysis, confocal microscopy, and tubulin polymerization inhibitory activity studies and promoted cell killing mediated by caspase-3 activation. Binding at the colchicine site was confirmed by means of fluorescence measurements of MTC displacement. Molecular modeling suggests that the tropolone-binding region of the colchicine site of tubulin can adapt to hosting small polar substituents. Isocombretastatins accepted substitutions better than phenstatins, and the highest potencies were achieved for the cyano and hydroxyiminomethyl substituents, with TPI values in the submicromolar range and cytotoxicities in the subnanomolar range. A 3,4,5-trimethoxyphenyl ring usually afforded more potent derivatives than a 2,3,4-trimethoxyphenyl ring., This work was supported by Spanish MEC (ref CTQ2004-00369/BQU), the EU (Structural Funds), Spanish MICINN (SAF 2008-04242), the Consejeria de Educación de la Junta de Castilla y León (SA067A09), and the AECID (PCIMediterraneo A1/037364/11). Different parts of the work were performed on the basis of financial support from the Consejeria de Educación de la Junta de Castilla y León (Programa de Apoyo a Proyectos de Investigacion, EDU/940/2009, CSI052A11-2, and CSI221A12-2), Spanish Ministerio de Economia y Competitividad (BIO2010-16351, SAF2008-02251, SAF2011-30518), Comunidad de Madrid (S2010/BMD-2457 BIPEDD2 to JFD), Red Tematica de Investigación Cooperativa en Cancer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union (RD06/0020/1037 and RD12/0036/0065) and the European Community’s Seventh Framework Programme FP7- 2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS). R.A. thanks the Spanish MEC for FPU and the Fundación Ramon Areces for a predoctoral grant., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine

  • Bonilla, Ximena
  • Dakir, El Habib
  • Mollinedo, Faustino
  • Gajate, Consuelo
This is an open-access article distributed under the terms of the Creative Commons Attribution License., Ewing’s sarcoma (ES) is the second most common bone cancer in children and young people. Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) is the prototype of a family of synthetic antitumor compounds, collectively known as alkylphospholipid analogs (APLs). We have found that APLs ranked edelfosine>perifosine>erucylphosphocholine>miltefosine for their capacity to promote apoptosis in ES cells. Edelfosine accumulated in the endoplasmic reticulum (ER) and triggered an ER stress response that eventually led to caspase-dependent apoptosis in ES cells. This apoptotic response involved mitochondrial-mediated processes, with cytochrome c release, caspase-9 activation and generation of reactive oxygen species. Edelfosine-induced apoptosis was also dependent on sustained c-Jun NH2-terminal kinase activation. Oral administration of edelfosine showed a potent in vivo antitumor activity in an ES xenograft animal model. Histochemical staining gave evidence for ER stress response and apoptosis in the ES tumors isolated from edelfosine-treated mice. Edelfosine showed a preferential action on ES tumor cells as compared to non-transformed osteoblasts, and appeared to be well suited for combination therapy regimens. These results demonstrate in vitro and in vivo antitumor activity of edelfosine against ES cells that is mediated by caspase activation and ER stress, and provide the proof of concept for a putative edelfosine- and ER stress-mediated approach forES treatment., This work was funded by grants from Spanish Ministerio de Ciencia e Innovación (SAF2011-30518, SAF2014-59716-R), European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS), Spanish Ministerio de Economia y Competitividad (RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), Fondo de Investigación Sanitaria and European Commission (FIS-FEDER PS09/01915), Junta de Castilla y León (CSI052A11-2 and Biomedicine Project 2010-2011). CG was supported by the Ramón y Cajal Program from the Ministerio de Ciencia e Innovación of Spain., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine

  • Gajate, Consuelo
  • Mollinedo, Faustino
The so-called alkylphospholipid analogs (APLs) constitute a family of synthetic antitumor compounds that target cell membranes. The ether phospholipid edelfosine has been considered the long-standing prototype of these antitumor agents and promotes apoptosis in tumor cells by a rather selective way, while sparing normal cells. Increasing evidence suggests that edelfosine-induced apoptosis involves a number of subcellular structures in tumor cells, including plasma membrane lipid rafts, endoplasmic reticulum (ER) and mitochondria. Edelfosine has been shown to accumulate in plasma membrane lipid rafts, ER and mitochondria in different tumor cells in a cell type-dependent way. Edelfosine induces apoptosis in several hematopoietic cancer cells by recruiting death receptor and downstream apoptotic signaling molecules into lipid rafts and displacing survival signaling molecules from these membrane domains. However, in vitro and in vivo evidences suggest that edelfosine-induced apoptosis in solid tumor cells is mediated through an ER stress response. Both raft- and ER-mediated proapoptotic responses require a mitochondrial-related step to eventually promote cell death, and overexpression of Bcl-2 or Bcl-xL prevents edelfosine-induced apoptosis. Edelfosine can also interact with mitochondria leading to an increase in mitochondrial membrane permeability and loss of mitochondrial membrane potential. Edelfosine treatment also induced a redistribution of lipid rafts from the plasma membrane to mitochondria, suggesting a raft-mediated link between plasma membrane and mitochondria. The involvement of lipid rafts, ER and mitochondria in the apoptotic response induced by edelfosine may provide new avenues for targeting cancer cells as well as new opportunities for cancer therapy., This work was supported by grants from Fondo de Investigación Sanitaria and European Commission, Instituto de Salud Carlos III (PS09/01915), Ministerio de Economia y Competitividad (SAF2011-30518), Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofounded by the Fondo Europeo de Desarrollo Regional of the European Union (RD12/0036/0065), European Community’s Seventh Framework Programme FP7-2007-2013 (Grant HEALTH-F2-2011-256986, PANACREAS), and Junta de Castilla y León (CSI221A12-2, and Biomedicine Project 2010-2011). CG is supported by the Ramón y Cajal Program from the Ministerio de Ciencia e Innovación of Spain., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lipid rafts and raft-mediated supramolecular entities in the regulation of CD95 death receptor apoptotic signaling

  • Gajate, Consuelo
  • Mollinedo, Faustino
Membrane lipid rafts are highly ordered membrane domains enriched in cholesterol, sphingolipids and gangliosides that have the property to segregate and concentrate proteins. Lipid and protein composition of lipid rafts differs from that of the surrounding membrane, thus providing sorting platforms and hubs for signal transduction molecules, including CD95 death receptor-mediated signaling. CD95 can be recruited to rafts in a reversible way through S-palmitoylation following activation of cells with its physiological cognate ligand as well as with a wide variety of inducers, including several antitumor drugs through ligand-independent intracellular mechanisms. CD95 translocation to rafts can be modulated pharmacologically, thus becoming a target for the treatment of apoptosis-defective diseases, such as cancer. CD95-mediated signaling largely depends on protein-protein interactions, and the recruitment and concentration of CD95 and distinct downstream apoptotic molecules in membrane raft domains, forming raft-based supramolecular entities that act as hubs for apoptotic signaling molecules, favors the generation and amplification of apoptotic signals. Efficient CD95-mediated apoptosis involves CD95 and raft internalization, as well as the involvement of different subcellular organelles. In this review, we briefly summarize and discuss the involvement of lipid rafts in the regulation of CD95-mediated apoptosis that may provide a new avenue for cancer therapy., The studies from our laboratory were supported by grants from Spanish Ministerio de Economia y Competitividad (SAF2011-30518; and RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), European Community’s Seventh Framework Programme FP7-2007-2013 (Grant HEALTH-F2-2011-256986, PANACREAS), and Junta de Castilla y León (CSI052A11-2 and CSI221A12-2)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lipid raft-mediated Fas/CD95 apoptotic signaling in leukemic cells and normal leukocytes and therapeutic implications

  • Gajate, Consuelo
  • Mollinedo, Faustino
Plasma membrane is now recognized to contain tightly packed cholesterol/sphingolipid-rich domains, known as lipid or membrane rafts, which are more ordered than the surrounding lipid bilayer. Lipid rafts are crucial for the compartmentalization of signaling processes in the membrane, mostly involved in cell survival and immune response. However, in the last 15 years, a large body of evidence has also identified raft platforms as scaffolds for the recruitment and clustering of death receptor Fas/CD95 and downstream signaling molecules, leading to the concept of death-promoting lipid rafts. This raft-Fas/CD95 coclustering was first described at the early 2000s as the underlying mechanism for the proapoptotic action of the alkylphospholipid analog edelfosine in leukemic cells, hence facilitating protein– protein interactions and conveying apoptotic signals independently of Fas/CD95 ligand. Edelfosine induces apoptosis in hematologic cancer cells and activated T-lymphocytes. Fas/CD95 raft coclustering is also promoted by Fas/CD95 ligand, agonistic Fas/CD95 antibodies, and additional antitumor drugs. Thus, death receptor recruitment in rafts is a physiologic process leading to cell demise that can be pharmacologically modulated. This redistribution and local accumulation of apoptotic molecules in membrane rafts, which are usually accompanied by displacement of survival signaling molecules, highlight how alterations in the apoptosis/survival signaling balance in specialized membrane regions modulate cell fate. Membrane rafts might also modulate apoptotic and nonapoptotic death receptor signaling.Here,wediscuss the role of lipid rafts in Fas/CD95-mediated apoptotic cell signaling in hematologic cancer cells and normal leukocytes, with a special emphasis on their involvement as putative therapeutic targets in cancer and autoimmune diseases., This work was supported by grants from European Community’s Seventh Framework Programme FP7-2007-2013 (Grant HEALTH-F2-2011-256986, PANACREAS)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Necroptosis is associated with low procaspase-8 and active RIPK1 and −3 in human glioma cells

  • Melo-Lima, Sara
  • Lopes, Maria Celeste
  • Mollinedo, Faustino
This is an open-access article distributed under the terms of the Creative Commons Attribution License., Necroptosis is a regulated necrotic cell death that involves receptor-interacting protein kinases RIPK1 and RIPK3. Here, we report that edelfosine triggers a rapid and massive cell death in human glioblastoma cells with characteristics of necrosis. Only a minor proportion of edelfosine-treated cells underwent caspase-dependent apoptosis. Autophagy and a rapid influx of extracellular calcium into the cells had little impact on cell death. Levels of procaspase-8 were very low in necroptosis-prone glioma cells compared with the levels in other cancer cell types that underwent apoptosis upon edelfosine treatment. The RIPK1-dependent necroptosis inhibitors necrostatin-1 (Nec-1) and Nec-1s as well as siRNA-mediated silencing of RIPK3 inhibited edelfosine-induced necroptosis, resulting in increased caspase-dependent apoptosis in edelfosine-treated glioblastoma U118 cells. Inhibition of the RIPK3 substrate MLKL with necrosulfonamide also increased apoptosis in edelfosine-treated cells. These data support a major role for RIPK1 and RIPK3 in the induction of necrotic cell death and in the switch from necrosis to apoptosis following edelfosine treatment. These results indicate that the ether lipid edelfosine exerts a rapid necroptotic cell death in apoptosis-reluctant glioblastoma cells, suggesting that induction of necroptosis could constitute a new approach for glioblastoma therapy., This work was supported by grants from the Spanish Ministerio de Ciencia e Innovación (SAF2011-30518), Spanish Ministerio de Economía y Competitividad (RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), Fundação para a Ciência e Tecnologia (SFRH/BD/46330/2008, Portuguese Ministério da Ciencia, Tecnología e Ensino Superior), European Community's Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS), and Junta de Castilla y León (CSI052A11-2). S.M.-L. was recipient of a predoctoral fellowship from the Fundação para a Ciência e Tecnologia (Ministério da Ciencia, Tecnología e Ensino Superior of Portugal)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

ERK1/2 acts as a switch between necrotic and apoptotic cell death in ether phospholipid edelfosine-treated glioblastoma cells

  • Melo-Lima, Sara
  • Lopes, Maria Celeste
  • Mollinedo, Faustino
Glioblastoma is characterized by constitutive apoptosis resistance and survival signaling expression, but paradoxically is a necrosis-prone neoplasm. Incubation of human U118 glioblastoma cells with the antitumor alkylphospholipid analog edelfosine induced a potent necrotic cell death, whereas apoptosis was scarce. Preincubation of U118 cells with the selective MEK1/2 inhibitor U0126, which inhibits MEK1/2-mediated activation of ERK1/2, led to a switch from necrosis to caspase-dependent apoptosis following edelfosine treatment. Combined treatment of U0126 and edelfosine totally inhibited ERK1/2 phosphorylation, and led to RIPK1 and RelA/NF-κB degradation, together with a strong activation of caspase-3 and -8. This apoptotic response was accompanied by the activation of the intrinsic apoptotic pathway with mitochondrial transmembrane potential loss, Bcl-xL degradation and caspase-9 activation. Inhibition of ERK phosphorylation also led to a dramatic increase in edelfosine-induced apoptosis when the alkylphospholipid analog was used at a low micromolar range, suggesting that ERK phosphorylation acts as a potent regulator of apoptotic cell death in edelfosine-treated U118 cells. These data show that inhibition of MEK1/2-ERK1/2 signaling pathway highly potentiates edelfosine-induced apoptosis in glioblastoma U118 cells and switches the type of edelfosine-induced cell death from necrosis to apoptosis., This work was supported by grants from the Spanish Ministerio de Ciencia e Innovación (SAF2011-30518), Spanish Ministerio de Economía y Competitividad (RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), Fundação para a Ciência e Tecnologia (SFRH/BD/46330/2008, Portuguese Ministério da Ciencia, Tecnología e Ensino Superior), European Community's Seventh Framework Programme FP7-2007–2013 (grant HEALTH-F2-2011-256986, PANACREAS), and Junta de Castilla y León (CSI052A11-2 and CSI221A12-2). S.M.-L. was recipient of a predoctoral fellowship from the Fundação para a Ciência e Tecnologia (Ministério da Ciencia, Tecnología e Ensino Superior of Portugal)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antitumor alkylphospholipid analogs: A promising and growing family of synthetic cell membrane-targeting molecules for cancer treatment

  • Mollinedo, Faustino
Editorial., F.M.’s team is supported by grants from Ministerio de Economia y Competitividad of Spain (SAF2011-30518), Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union (RD12/0036/0065), European Community’s Seventh Framework Programme FP7-2007-2013 (Grant HEALTHF2-2011-256986, PANACREAS), and Junta de Castilla y León (CSI221A12-2)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lipid rafts as major platforms for signaling regulation in cancer

  • Mollinedo, Faustino
  • Gajate, Consuelo
Cell signaling does not apparently occur randomly over the cell surface, but it seems to be integrated very often into cholesterol-rich membrane domains, termed lipid rafts. Membrane lipid rafts are highly ordered membrane domains that are enriched in cholesterol, sphingolipids and gangliosides, and behave as major modulators of membrane geometry, lateral movement of molecules, traffic and signal transduction. Because the lipid and protein composition of membrane rafts differs from that of the surrounding membrane, they provide an additional level of compartmentalization, serving as sorting platforms and hubs for signal transduction proteins. A wide number of signal transduction processes related to cell adhesion, migration, as well as to cell survival and proliferation, which play major roles in cancer development and progression, are dependent on lipid rafts. Despite lipid rafts harbor mainly critical survival signaling pathways, including insulin-like growth factor I (IGF-I)/phosphatidylinositol 3-kinase (PI3K)/Akt signaling, recent evidence suggests that these membrane domains can also house death receptor-mediated apoptotic signaling. Recruitment of this death receptor signaling pathway in membrane rafts can be pharmacologically modulated, thus opening up the possibility to regulate cell demise with a therapeutic use. The synthetic ether phospholipid edelfosine shows a high affinity for cholesterol and accumulates in lipid rafts in a number of malignant hematological cells, leading to an efficient invitro and invivo antitumor activity by inducing translocation of death receptors and downstream signaling molecules to these membrane domains. Additional antitumor drugs have also been shown to act, at least in part, by recruiting death receptors in lipid rafts. The partition of death receptors together with downstream apoptotic signaling molecules in membrane rafts has led us to postulate the concept of a special liquid-ordered membrane platform coined as >. cluster of apoptotic signaling molecule- enriched rafts> (CASMER), referring to raft platforms enriched in apoptotic molecules. CASMERs act as scaffolds for apoptosis signaling compartmentalization, facilitating and stabilizing protein-protein interactions by local assembly of cross-interacting molecules, which leads to apoptosis amplification and a decrease in apoptotic signal threshold. Edelfosine also displaced survival PI3K/Akt signaling from lipid rafts, leading to Akt inhibition, in mantle cell lymphoma cells. Thus, membrane rafts could act as scaffold structures where segregation of pro- from anti-apoptotic molecules could take place. In this review, we summarize our view of how reorganization of the protein composition of lipid raft membrane domains regulates cell death and therefore it might be envisaged as a novel target in the treatment of cancer., This work was supported by the Spanish Ministerio de Ciencia e Innovación (SAF2011-30518), Spanish Ministerio de Economía y Competitividad (RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), and European Community's Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS), Fondo de Investigación Sanitaria and European Commission (FIS-FEDER PS09/01915), and Junta de Castilla y León (CSI052A11-2 and Biomedicine Project 2010–2011). CG was supported by the Ramón y Cajal Program from the Ministerio de Ciencia e Innovación of Spain., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Arginase activity and CD3ζ expression after major surgery

  • Palomero Rodríguez, Miguel Ángel
  • García-Navas, Rósula
  • Mollinedo, Faustino
Letter.-- et al., The studies from our laboratory were supported by grants from Spanish Ministerio de Economia y Competitividad (SAF2011-30518; and RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), the European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS), and Junta de Castilla y León (CSI052A11-2 and CSI221A12-2)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Caenorhabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipids

  • Sánchez-Blanco, Adolfo
  • Rodríguez-Matellán, Alberto G.
  • Reis-Sobreiro, M.
  • Sáenz-Narciso, Beatriz
  • Cabello, Juan
  • Mohler, William A.
  • Mollinedo, Faustino
Drugs capable of specifically recognizing and killing cancer cells while sparing healthy cells are of great interest in anti-cancer therapy. An example of such a drug is edelfosine, the prototype molecule of a family of synthetic lipids collectively known as antitumor lipids (ATLs). A better understanding of the selectivity and the mechanism of action of these compounds would lead to better anticancer treatments. Using Caenorhabditis elegans, we modeled key features of the ATL selectivity against cancer cells. Edelfosine induced a selective and direct killing action on C. elegans embryos, which was dependent on cholesterol, without affecting adult worms and larvae. Distinct ATLs ranked differently in their embryonic lethal effect with edelfosine > perifosine > erucylphosphocholine >> miltefosine. Following a biased screening of 57 C. elegans mutants we found that inactivation of components of the insulin/IGF-1 signaling pathway led to resistance against the ATL edelfosine in both C. elegans and human tumor cells. This paper shows that C. elegans can be used as a rapid platform to facilitate ATL research and to further understand the mechanism of action of edelfosine and other synthetic ATLs., This work was supported by grants from the Spanish Ministerio de Ciencia e Innovación (SAF2011–30518), Spanish Ministerio de Economía y Competitividad (RD12/0036/0065, Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), European Community’s Seventh Framework Program FP7-2007-2013 (grant HEALTH-F2–2011–256986, PANACREAS), and Junta de Castilla y León (CSI052A11–2). ASB was supported by the CSIC JAE-Doc program., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The HSP90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine

  • Varela-M, Rubén E.
  • Mollinedo-Gajate, Cristina
  • Muro, Antonio
  • Mollinedo, Faustino
HSP90 is an abundant protein in Leishmania parasites that plays a major role in the parasite survival under stress conditions. Here we found that the HSP90 inhibitor 17-AAG (≥100nM 17-AAG) induced cell cycle arrest at G0/G1 in Leishmania infantum and Leishmania panamensis promastigotes, and highly potentiated the induction of cell death by an apoptotic-like process mediated by the ether phospholipid edelfosine (5-20μM). These data suggest that the combined treatment of 17-AAG and edelfosine might be a novel and effective approach of combination therapy in the treatment of leishmaniasis., This work was supported by grants from Ministerio de Economía y Competitividad of Spain (SAF2011-30518), Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union (RD12/0036/0065), Junta de Castilla y León (CSI052A11-2 and CSI221A12-2), and Fundación Ramón Areces 2010-13. REVM was supported by a Torres Quevedo fellowship from the Ministerio de Ciencia e Innovación of Spain., European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986 - PANACREAS)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine

  • Yepes, Edward
  • Varela-M, Rubén E.
  • López-Abán, Julio
  • Dakir, El Habib
  • Mollinedo, Faustino
  • Muro, Antonio
This is an open-access article distributed under the terms of the Creative Commons Attribution License., [Background]: Schistosomiasis is a parasitic disease caused by trematodes of the genus Schistosoma. Five species of Schistosoma are known to infect humans, out of which S. haematobium is the most prevalent, causing the chronic parasitic disease schistosomiasis that still represents a major problem of public health in many regions of the world and especially in tropical areas, leading to serious manifestations and mortality in developing countries. Since the 1970s, praziquantel (PZQ) is the drug of choice for the treatment of schistosomiasis, but concerns about relying on a single drug to treat millions of people, and the potential appearance of drug resistance, make identification of alternative schistosomiasis chemotherapies a high priority. Alkylphospholipid analogs (APLs), together with their prototypic molecule edelfosine (EDLF), are a family of synthetic antineoplastic compounds that show additional pharmacological actions, including antiparasitic activities against several protozoan parasites. [Methodology/Principal Findings]: We found APLs ranked edelfosine> perifosine> erucylphosphocholine> miltefosine for their in vitro schistosomicidal activity against adult S. mansoni worms. Edelfosine accumulated mainly in the worm tegument, and led to tegumental alterations, membrane permeabilization, motility impairment, blockade of male-female pairing as well as induction of apoptosis-like processes in cells in the close vicinity to the tegument. Edelfosine oral treatment also showed in vivo schistosomicidal activity and decreased significantly the egg burden in the liver, a key event in schistosomiasis. [Conclusions/Significance]: Our data show that edelfosine is the most potent APL in killing S. mansoni adult worms in vitro. Edelfosine schistosomicidal activity seems to depend on its action on the tegumental structure, leading to tegumental damage, membrane permeabilization and apoptosis-like cell death. Oral administration of edelfosine diminished worm and egg burdens in S. mansoni -infected CD1 mice. Here we report that edelfosine showed promising antischistosomal properties in vitro and in vivo., This work was supported by the Spanish Ministerio de Ciencia e Innovación (SAF2011-30518, and RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), European Community's Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS), Junta de Castilla y León (CSI052A11-2and SA342U13), Sociedad Española de Medicina Tropical y Salud Internacional (RFEF-SEMTSI 2013) and the Universidad de Salamanca (USAL17008)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inhibition of granulomatous inflammation and prophylactic treatment of schistosomiasis with a combination of edelfosine and Praziquantel

  • Yepes, Edward
  • Varela-M, Rubén E.
  • López-Abán, Julio
  • Rojas-Caraballo, Jose
  • Muro, Antonio
  • Mollinedo, Faustino
This is an open access article distributed under the terms of the Creative Commons Attribution License., [Background]: Schistosomiasis is the third most devastating tropical disease worldwide caused by blood flukes of the genus Schistosoma. This parasitic disease is due to immunologic reactions to Schistosoma eggs trapped in tissues. Egg-released antigens stimulate tissue-destructive inflammatory and granulomatous reactions, involving different immune cell populations, including T cells and granulocytes. Granulomas lead to collagen fibers deposition and fibrosis, resulting in organ damage. Praziquantel (PZQ) is the drug of choice for treating all species of schistosomes. However, PZQ kills only adult Schistosoma worms, not immature stages. The inability of PZQ to abort early infection or prevent re-infection, and the lack of prophylactic effect prompt the need for novel drugs and strategies for the prevention of schistosomiasis. [Methodology/Principal Findings]: Using in vitro and in vivo approaches, we have found that the alkylphospholipid analog edelfosine kills schistosomula, and displays anti-inflammatory activity. The combined treatment of PZQ and edelfosine during a few days before and after cercariae infection in a schistosomiasis mouse model, simulating a prophylactic treatment, led to seven major effects: a) killing of Schistosoma parasites at early and late development stages; b) reduction of hepatomegaly; c) granuloma size reduction; d) down-regulation of Th1, Th2 and Th17 responses at late post-infection times, thus inhibiting granuloma formation; e) upregulation of IL-10 at early post-infection times, thus potentiating anti-inflammatory actions; f) down-regulation of IL-10 at late post-infection times, thus favoring resistance to re-infection; g) reduction in the number of blood granulocytes in late post-infection times as compared to infected untreated animals. [Conclusions/Significance]: Taken together, these data suggest that the combined treatment of PZQ and edelfosine promotes a high decrease in granuloma formation, as well as in the cellular immune response that underlies granuloma development, with changes in the cytokine patterns, and may provide a promising and effective strategy for a prophylactic treatment of schistosomiasis., This work was supported by grants from the Junta de Castilla y León (SA342U13, CSI052A11-2, and CSI221A12-2), Real Federación Española de Fútbol-Sociedad Española de Medicina Tropical y Salud Internacional (RFEF-SEMTSI 2013), Spanish Ministerio de Economía y Competitividad (SAF2011-30518, SAF2014-59716-R, and RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), and European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dietary and microbiome factors determine longevity in Caenorhabditis elegans

  • Sánchez-Blanco, Adolfo
  • Rodríguez-Matellán, Alberto G.
  • González-Paramas, Ana
  • González-Manzano, Susana
  • Kim, Stuart K.
  • Mollinedo, Faustino
Diet composition affects organismal health. Nutrient uptake depends on the microbiome. Caenorhabditis elegans fed a Bacillus subtilis diet live longer than those fed the standard Escherichia coli diet. Here we report that this longevity difference is primarily caused by dietary coQ, an antioxidant synthesized by E. coli but not by B. subtilis. CoQ‐supplemented E. coli fed worms have a lower oxidation state yet live shorter than coQ‐less B. subtilis fed worms. We showed that mutations affecting longevity for E. coli fed worms do not always lead to similar effects when worms are fed B. subtilis. We propose that coQ supplementation by the E. coli diet alters the worm cellular REDOX homeostasis, thus decreasing longevity. Our results highlight the importance of microbiome factors in longevity, argue that antioxidant supplementation can be detrimental, and suggest that the C. elegans standard E. coli diet can alter the effect of signaling pathways on longevity., This work was supported by grants to FM from the Spanish Ministerio de Economía y Competitividad (SAF2011-30518, SAF2014-59716-R, and RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), and European Community’s 7th Framework Programme (HEALTH-F2-2011-256986, PANACREAS). AS-B was supported by the CSIC JAEDoc program and by the Stanford Center on Longevity. The Grupo de Investigación en Polifenoles was supported by the Spanish Ministerio de Economía y Competitividad (BFU2012-35228)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The alkylphospholipid edelfosine shows activity against Strongyloides venezuelensis and induces apoptosis-like cell death

  • Legarda-Ceballos, Ana L.
  • Rojas-Caraballo, Jose
  • López-Abán, Julio
  • Ruano, A. L.
  • Yepes, Edward
  • Gajate, Consuelo
  • Mollinedo, Faustino
  • Muro, Antonio
33 p.-6 fig.-1 tab., Strongyloidiasis is widely distributed in the tropical and subtropical areas. Ivermectin is the drug of choice for the treatment. However, the concerns about relying treatment on a single drug make identification of new molecules a priority. Alkylphospholipid analogues, including edelfosine, are a group of synthetic compounds that have shown activity against some parasites. The objective was to assess the in vitro and in vivo activity of edelfosine, miltefosine, perifosine against Strongyloides venezuelensis. Moreover, apoptosis-like mechanism in larvae after treatment was studied. Edelfosine displayed the highest activity and the best selectivity index (LD50 = 49.6 ± 5.4 μM, SI = 1.1) compared to miltefosine or perifosine. Third stage larvae after culture with edelfosine were not able to develop an infection in mice. Treatment of mice with edelfosine showed reduction of 47% in parasitic females allocated in the gut. Moreover, DNA fragmentation was observed by TUNEL staining in larvae treated with edelfosine. These results suggest that edelfosine could be an effective drug against strongyloidiasis, probably through induction of apoptosis-like cell death., This work has been supported by Proyectos Integrados IBSAL (IBY15/00003; Salamanca, Spain; Spanish Ministerio de Economía y Competitividad (SAF2011-30518, SAF2014-59716-R, and RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional of the European Union), and the European Union’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy

  • Jaffrès, Paul-Alain
  • Gajate, Consuelo
  • Bouchet, Ana Maria
  • Couthon-Gourvès, Hélène
  • Chantôme, Aurélie
  • Potier-Cartereau, Marie
  • Besson, Pierre
  • Bougnoux, Philippe
  • Mollinedo, Faustino
  • Vandier, Christophe
64 p.-6 fig., Synthetic alkyl lipids, such as the ether lipids edelfosine (1-O-octadecyl-2-O-methyl-rac- glycero-3-phosphocholine) and ohmline (1-O-hexadecyl-2-O-methyl-rac-glycero-3-β- lactose), are forming a class of antitumor agents that target cell membranes to induce apoptosis and to decrease cell migration/invasion, leading to the inhibition of tumor and metastasis development. In this review, we present the structure-activity relationship of edelfosine and ohmline, and we point out differences and similarities between these two amphiphilic compounds. We also discuss the mechanisms of action of these synthetic alkyl ether lipids (involving, among other structures and molecules, membrane domains, Fas/CD95 death receptor signaling, and ion channels), and highlight a key role for lipid rafts in the underlying process. The reorganization of lipid raft membrane domains induced by these alkyl lipids affects the function of death receptors and ion channels, thus leading to apoptosis and inhibition of cancer cell migration. The possible therapeutic use of these alkyl lipids and the clinical perspectives for these lipids in prevention or/and treatment of tumor development and metastasis are also discussed., This work was supported by the Agence Nationale de la Recherche N°ANR-08-EBIO-020-01, la Ligue Contre le Cancer, Region Centre (LIPIDS project of ARD2020-Biomédicaments), INSERM, CNRS, Cancéropôle Grand Ouest, the association “CANCEN”, Tours’ Hospital oncology association ACORT", grants from Spanish Ministerio de Economia y Competitividad (SAF2011-30518, SAF2014-59716-R, and RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), and European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011- 256986, PANACREAS). Ana Bouchet holds a post-doc mobility grant from PRESTIGE-European FP7 / University of Tours., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine

  • Villa-Pulgarín, J. A.
  • Gajate, Consuelo
  • Botet, Javier
  • Jiménez, Alberto
  • Justies, Nicole
  • Varela-M, Rubén E.
  • Cuesta-Marbán, Álvaro
  • Müller, Ingrid
  • Modolell, Manuel
  • Revuelta Doval, José Luis
  • Mollinedo, Faustino
[Background]:Leishmaniasis is the world's second deadliest parasitic disease after malaria, and current treatment of the different forms of this disease is far from satisfactory. Alkylphospholipid analogs (APLs) are a family of anticancer drugs that show antileishmanial activity, including the first oral drug (miltefosine) for leishmaniasis and drugs in preclinical/clinical oncology trials, but their precise mechanism of action remains to be elucidated., [Methodology/Principal Findings]:Here we show that the tumor cell apoptosis-inducer edelfosine was the most effective APL, as compared to miltefosine, perifosine and erucylphosphocholine, in killing Leishmania spp. promastigotes and amastigotes as well as tumor cells, as assessed by DNA breakdown determined by flow cytometry. In studies using animal models, we found that orally-administered edelfosine showed a potent in vivo antileishmanial activity and diminished macrophage pro-inflammatory responses. Edelfosine was also able to kill Leishmania axenic amastigotes. Edelfosine was taken up by host macrophages and killed intracellular Leishmania amastigotes in infected macrophages. Edelfosine accumulated in tumor cell mitochondria and Leishmania kinetoplast-mitochondrion, and led to mitochondrial transmembrane potential disruption, and to the successive breakdown of parasite mitochondrial and nuclear DNA. Ectopic expression of Bcl-XL inhibited edelfosine-induced cell death in both Leishmania parasites and tumor cells. We found that the cytotoxic activity of edelfosine against Leishmania parasites and tumor cells was associated with a dramatic recruitment of FOF1-ATP synthase into lipid rafts following edelfosine treatment in both parasites and cancer cells. Raft disruption and specific FOF1-ATP synthase inhibition hindered edelfosine-induced cell death in both Leishmania parasites and tumor cells. Genetic deletion of FOF1-ATP synthase led to edelfosine drug resistance in Saccharomyces cerevisiae yeast., [Conclusions/Significance]:The present study shows that the antileishmanial and anticancer actions of edelfosine share some common signaling processes, with mitochondria and raft-located FOF1-ATP synthase being critical in the killing process, thus identifying novel druggable targets for the treatment of leishmaniasis., This work was supported by grants from the Spanish Ministerio de Economia y Competitividad (SAF2014-59716-R and BIO2014-56930-P), Instituto de Salud Carlos III (RD12/0036/0065 from Red TemaÂtica de Investigación Cooperativa en Cáncer, cofunded by the EU's European Regional Development Fund ± FEDER),European Community's Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS), and Spain-UK International Joint Project grant from The Royal Society-CSIC (2004GB0032). CG was supported by the RamoÂn y Cajal Program from the Spanish Ministerio de Ciencia e Innovación.AÂCM was recipient of Formación de Profesorado Universitario predoctoral fellowship from the Spanish Ministerio de Ciencia e Innovación., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells

  • Bello, Claudia
  • Gajate, Consuelo
  • Mollinedo, Faustino
  • Vogel, Pierre
57 p.-9 fig.-2 tab.+Graph. Abst.+Suppl.mat. Bello, Claudia et al., We have synthesized a wide array of structurally related amphiphilic compounds, containing a functionalized pyrrolidine polar group coupled to different ether-linked hydrocarbon chains, to generate novel structures with antitumor activity. These newly synthesized amphiphilic pyrrolidine-derived compounds were classified in three different sub-libraries regarding the number of hydroxyl groups substituting the pyrrolidine moiety at C3 and C4. Pyrrolidine compounds with one or none hydroxyl groups showed a potent cell killing activity against pancreatic cancer cells, but they lacked selectivity for tumor cells. Pyrrolidine compounds with two hydroxyl groups induced cell death in a wide variety of pancreatic cancer cell lines, and they were somewhat less cytotoxic to normal non-tumor cells. Among these latter compounds, the diol-derived pyrrolidine 20 ((2R,3R,4S)-2-{(9Z)-hexadec-9-en-1-yloxy] methyl}pyrrolidine-3,4-diol) induced autophagy and a potent apoptotic response in pancreatic ductal adenocarcinoma cells, which was inhibited by Bcl-XL overexpression and by caspase inhibition, in a way similar to that of the amphiphilic ether lipid edelfosine, with which it was compared. Pharmacological and genetic inhibition of autophagy potentiated 20-mediated apoptosis. These structure-activity relationship studies point out the importance of the diol polar group and aliphatic side chain of 20 in promoting apoptosis against pancreatic cancer cells in a rather controlled way, and some additional subtle modifications were found to be potential modulators of the cytotoxic activity., This work was supported by the European Community's Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS), the Swiss National Science Foundation,the EPFL for a Innogrant to C.B., the Associazione Italiana per la ricerca sul cancro (AIRC), Ministerio de Ciencia e Innovación of Spain CTQ2012-31247, Spanish Ministerio de Economia y Competitividad (SAF2014-59716-R, SAF2017-89672-R and CTQ2016-77270-R), and Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, co-funded by the Fondo Europeo de Desarrollo Regional of the European Union (RD12/ 0036/0065)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Antitumor activity of Lepidium latifolium and identification of the epithionitrile 1-cyano-2,3-epithiopropane as its major active component

  • Conde-Rioll, María
  • Gajate, Consuelo
  • Fernández, José J.
  • Villa-Pulgarín, J. A.
  • Napolitano, José G.
  • Norte, Manuel
  • Mollinedo, Faustino
Consumption of Brassica (Cruciferae) vegetables is associated with a reduced risk of cancer, but identification of the active components and insights into the underlying molecular events are scarce. Here we found that an extract of Lepidium latifolium, a cruciferous plant native to southern Europe, Mediterranean countries and Asia, showed in vitro cytotoxic activity, inducing caspase-dependent apoptosis, in a variety of human tumor cells, and the plant juice showed in vivo antitumor activity in a HT-29 human colon cancer xenograft mouse model. The epithionitrile 1-cyano-2,3-epithiopropane (CETP) was identified as the major active cancer cell-killing principle of L. latifolium. Synthetic and plant-derived CETP displayed similar proapoptotic activities as assessed by biochemical and morphological analyses. Analysis of the antiproliferative capacity of CETP on a wide number of cancer cell lines from the NCI-60 cell line panel followed by COMPARE analysis, showed an activity profile different from known anticancer agents. Flow cytometry and biochemical analyses revealed that CETP-induced apoptosis involved mitochondria, as assessed by loss of mitochondrial transmembrane potential and generation of reactive oxygen species, while overexpression of Bcl-X and Bcl-2 prevented CETP-induced apoptosis. Inhibition of reactive oxygen species by glutathione and N-acetyl cysteine reduced the apoptotic response induced by CETP. FADD dominant negative form, blocking Fas/CD95 signaling, and a specific caspase-8 inhibitor also inhibited CETP-induced killing. Taken together, our data suggest that the cancer cell-killing action of CETP, involving both intrinsic and extrinsic apoptotic signaling pathways, underlies the antitumor activity of L. latifolium plant, which could be of potential interest in cancer treatment., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2011-30518; SAF2014-59716-R; CTQ2014-55888-C03-01-R), Instituto de Salud Carlos III (RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer, cofunded by the EU's European Regional Development Fund—FEDER), and the European Community's Seventh Framework Programme FP7-2007-2013 (HEALTH-F2-2011-256986, PANACREAS)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer

  • Bai, Jian-Fei
  • Majjigapu, Somi Reddy
  • Sordat, Bernard
  • Poty, Sophie
  • Vogel, Pierre
  • Elías-Rodríguez, Pilar
  • Moreno-Vargas, Antonio J.
  • Carmona, Ana T.
  • Caffa, Irene
  • Ghanem, Moustafa
  • Khalifa, Amr
  • Monacelli, Fiammetta
  • Cea, Michele
  • Robina, Inmaculada
  • Gajate, Consuelo
  • Mollinedo, Faustino
  • Bellotti, Axel
  • Nahimana, Aimable
  • Duchosal, Michel
  • Nencioni, Alessio
11 p.- 2 fig.-4 tab.-8 schem.-1 graph. abst., Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases for which chemotherapy has not been very successful yet. FK866 ((E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide) is a well-known NAMPT (nicotinamide phosphoribosyltransferase) inhibitor with anti-cancer activities, but it failed in phase II clinical trials. We found that FK866 shows anti-proliferative activity in three PDAC cell lines, as well as in Jurkat T-cell leukemia cells. More than 50 FK866 analogues were synthesized that introduce substituents on the phenyl ring of the piperidine benzamide group of FK866 and exchange its buta-1,4-diyl tether for 1-oxyprop-3-yl, (E)-but-2-en-1,4-diyl and 2- and 3-carbon tethers. The pyridin-3-yl moiety of FK866 was exchanged for chlorinated and fluorinated analogues and for pyrazin-2-yl and pyridazin-4-yl groups. Several compounds showed low nanomolar or sub-nanomolar cell growth inhibitory activity. Our best cell anti-proliferative compounds were the 2,4,6-trimethoxybenzamide analogue of FK866 ((E)-N-(4-(1-(2,4,6-trimethoxybenzoyl)piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide) (9), the 2,6-dimethoxybenzamide (8) and 2-methoxybenzamide (4), which exhibited an IC50 of 0.16 nM, 0.004 nM and 0.08 nM toward PDAC cells, respectively., The research leading to these results has received funding from the European Community's Seventh Framework Programme [FP7-2007-2013] under grant agreement no. 256986 (PANACREAS), from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813284 (INTEGRATA), by the Spanish Ministry of Science, Innovation, and Universities (SAF2017-89672-R) and by the Associazione Italiana per la Ricerca sul Cancro (AIRC), IG#22098., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Suppression of metastatic organ colonization and antiangiogenic activity of the orally bioavailable lipid raft-targeted alkylphospholipid edelfosine

  • Alonso-Pérez, Verónica
  • Hernández, Vanessa
  • Calzado, Marco A.
  • Vicente-Blázquez, Alba
  • Gajate, Consuelo
  • Soler-Torronteras, Rafael
  • DeCicco-Skinner, Kathleen
  • Sierra, Angels
  • Mollinedo, Faustino
17 p.-8 fig., Metastasis is the leading cause of cancer mortality. Metastatic cancer is notoriously difficult to treat, and it accounts for the majority of cancer-related deaths. The ether lipid edelfosine is the prototype of a family of synthetic antitumor compounds collectively known as alkylphospholipid analogs, and its antitumor activity involves lipid raft reorganization. In this study, we examined the effect of edelfosine on metastatic colonization and angiogenesis. Using non-invasive bioluminescence imaging and histological examination, we found that oral administration of edelfosine in nude mice significantly inhibited the lung and brain colonization of luciferase-expressing 435-Lung-eGFP-CMV/Luc metastatic cells, resulting in prolonged survival. In metastatic 435-Lung and MDA-MB-231 breast cancer cells, we found that edelfosine also inhibited cell adhesion to collagen-I and laminin-I substrates, cell migration in chemotaxis and wound-healing assays, as well as cancer cell invasion. In 435-Lung and other MDA-MB-435-derived sublines with different organotropism, edelfosine induced G2/M cell cycle accumulation and apoptosis in a concentration- and time-dependent manner. Edelfosine also inhibited in vitro angiogenesis in human and mouse endothelial cell tube formation assays. The antimetastatic properties were specific to cancer cells, as edelfosine had no effects on viability in non-cancerous cells. Edelfosine accumulated in membrane rafts and endoplasmic reticulum of cancer cells, and membrane raft-located CD44 was downregulated upon drug treatment. Taken together, this study highlights the potential of edelfosine as an attractive drug to prevent metastatic growth and organ colonization in cancer therapy. The raft-targeted drug edelfosine displays a potent activity against metastatic organ colonization and angiogenesis, two major hallmarks of tumor malignancy., This work was supported by grants PID2020–119656RB-I00 (to FM) and PID2021–124314OB-I00 (to MAC) funded by MCIN/AEI/10.13039/501100011033 from the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), as well as by grants from the Spanish Ministry of Science, Innovation and Universities and Ministry of Economy and Competitiveness (SAF2017–89672-R, SAF2014–59716-R, and SAF2008–02251) (to FM), Spanish Ministry of Health and Consumer Affairs, the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) – FIS-PI14/00336 and FIS-PI18/00916 (to AS), Generalitat de Catalunya and Fundació Privada Cellex Barcelona (2014 SGR 530) (to AS), Consejería de Salud of the Junta de Andalucía (PI-0246–2013) (to MAC), RD06/0020/1037 and RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer-Instituto de Salud Carlos III (RTICC-ISCIII), cofunded by the EU's European Regional Development Fund – FEDER (to FM), and European Community’s Seventh Framework Program FP7–2007-2013 (grant HEALTH-F2–2011-256986) (to FM). V.A.-P. acknowledges a predoctoral project-based fellowship from the Ministry of Science and Innovation (BES-2009–024462), and a short-term fellowship from the RTICC-ISCIII., Peer reviewed